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STRESS-DEPRIVATION UNCOUPLES
METALLOPROTEINASE AND INHIBITOR EXPRESSION AND
REDUCES MATERIAL PROPERTIES OF DISTINCT TENDON
REGIONS
J.L. Peterson1, M.M. Smith1, R.C. Appleyard2, C.B. Little1
1Raymond Purves Bone and Joint Res. Lab., The Kolling Inst. of
Med. Res., Univ. of Sydney, Royal North Shore Hosp., St
Leonards, Australia; 2Murray Maxwell Biomechanics Lab., The
Kolling Inst. of Med. Res., Univ. of Sydney, Royal North Shore
Hosp., St Leonards, Australia
Purpose: Tendon injury is associated with microtears of collagen
ﬁbrils leading to regions of stress deprivation (SD). Increased met-
alloproteinase expression and activity induced by SD can further
degrade the matrix, alter tendon material properties, and lead
to catastrophic failure. We have observed topographically distinct
changes in MMP & ADAMTS expression in tendon degeneration
in vivo. The objective of this study was to determine if this repre-
sents inherent regional differences in the response of tenocytes to
altered loading.
Methods: Ovine infraspinatus tendons were dissected into 4 re-
gions (see ﬁgure). Tendon strips were frozen (ex-vivo), or cultured
SD for 1, 5 and 15 days (n=5). Ultimate tensile stress (UTS), strain
at failure (εfail), and elastic modulus (E) were determined in uni-
axial tension (10% strain/second). ADAMTS- and MMP-generated
aggrecan neoepitopes (NITEGE and DIPEN) were examined by
Western blotting of tendon extracts. Gene expression and gly-
cosaminoglycan (GAG) content were measured ex-vivo and in 1,
5 and 15-day cultures.
Results: There was no difference in material properties between
regions ex-vivo. Tensile tendon (regions 3&4) contained 47% less
GAG than regions near bone (1&2) (p < 0.001). There was no
regional difference ex-vivo in expression of ADAMTS-1, -4 or-5
or MMP-1, -2, -3, or -13. Compared with 1&2, MMP-9 & -14
expression was less (46% & 55%) in regions 3&4 and TIMP
expression was lower in region 4. Material properties and GAG
content were unchanged in any region with 1 and 5 days SD.
GAG was reduced only in regions 1&2 (44-48%, p<0.05) with
15 days SD, to be at the same level as 3&4. UTS and E (but
not εfail) were reduced in all regions after 15 days SD, the effect
being most marked in regions 3&4 (p<0.05 for UTS). NITEGE and
DIPEN decreased in all regions by 15 days SD. Gene expression
changes with SD were similar in direction and magnitude between
regions. ADAMTS-1, -4, -5 mRNA increased (10-1000 fold) after 1
day, then returned to ex vivo levels by 15 days, except in region 4
where ADAMTS-5 remained elevated. TIMP-3 mRNA decreased
90% by 1 day, and remained decreased (95%) to day 15. MMP -1,
-2, -3, -9, -13, & -14 mRNA increased with SD (20 - 20000-fold)
in all regions. MMP-mRNAs were all maximal by 5, and for -2, -9,
-13 & -14 they remained elevated, while MMP-1, -3 declined at
15 days. TIMP-1 increased 5-10 fold at day 1 and 2-5 fold at day
15. TIMP-2 mRNA decreased 50-90% with 1 day SD and then
returned to ex-vivo levels (or higher in region 4).
Figure 1
Conclusions: Although there were ex-vivo difference in GAG be-
tween regions, this did not equate to different material properties.
There was no regional difference in ADAMTS expression ex vivo,
suggesting this is not regulating lower GAG in tensile tendon.
However, lower ex-vivo MMP-9 and -14 in tensile tendon and
lower TIMPs in region 4, may suggest basal regional differences
in matrix remodeling. MMP, ADAMTS and TIMP expression rapidly
became uncoupled by SD in favour of increased matrix turnover
in all tendon regions. Changes in material properties with 15 days
SD culture could not be explained by altered GAG content nor
aggrecan proteolysis by ADAMTS or MMPs. Taken together these
data suggest that despite regional differences in tendon composi-
tion, the response of tenocytes from all tendon regions to SD is
similar.
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TILUDRONATE IN AN EXPERIMENTAL DOG MODEL OF
OSTEOARTHRITIS: BONE ANTI-RESORPTIVE ACTIVITY
AND RELATED FUNCTIONAL IMPROVEMENT
M. Moreau1, P. Rialland1, J.-P. Pelletier2, J. Martel-Pelletier2,
D. Lajeunesse2, C. Boileau2, J. Caron2, G. Beauchamp1,
D. Gauvin1, E. Troncy1
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Purpose: The aim of this controlled, prospective, randomized and
blinded study was to evaluate the effectiveness of tiludronate,
a sulphured bisphosphonate, to limit structural, biochemical and
molecular changes in the joint and to preserve the functional ability
in an experimental dog model of osteoarthritis (OA). The extent of
joint damage and functional impairment is hypothesised to be of
less magnitude in dogs with prophylactic tiludronate treatment as
compared to OA controls.
Methods: Baseline values were established the week preceding
surgical sectioning of the right knee cranial cruciate ligament,
with eight dogs serving as OA controls and eight others receiving
four tiludronate injections (2 mg/kg subcutaneous) at two-week
intervals starting the day of surgery until 8 weeks.
At baseline, week 4 and week 8, the functional outcome was de-
scribed using objective gait analysis, locomotor activity recording
and video-automated behaviour capture (except week 4 for this
evaluation). Functional impairment was assessed using a subjec-
tive multiparametric pain scale. Electrodermal activity (EDA) was
an indirect quantiﬁcation of pain. At necropsy (week 8), macro-
scopic and histomorphological analyses of synovium, cartilage and
subchondral bone of the femoral condyles and tibial plateaus were
assessed. Immunohistochemistry of cartilage (MMP-1, MMP-13,
and ADAMTS-5) and subchondral bone (MMP-13 and cathepsin K)
was performed. Synovial ﬂuid was analyzed for biochemical inﬂam-
matory (PGE2 and nitrite/nitrate levels) biomarkers. General linear
model for repeated measures and non-parametric Mann-Whitney
U-test, when necessary, were performed with an α-threshold of
0.05.
Results: A better functional outcome was observed in tiludronate-
treated dogs than OA controls. Hence, the gait disability was lower
and reached statistical signiﬁcance at week 8 (p=0.05). The lo-
comotor activity was higher at week 4 (p<0.03). Behaviours of
painless condition were observed at week 8 (p<0.03) with the
video-capture. One component of the pain scale was improved at
week 8 (p<0.05). Finally, the painful condition (EDA) was less pro-
nounced at week 4 (p=0.059).Macroscopically, tiludronate-treated
dogs had smaller joint effusion (p<0.05), and both the synovial
levels of PGE2 and nitrite/nitrate were reduced (p<0.05). Histo-
logically, the synovitis score was lower (p<0.01) and a greater
surface and thickness of subchondral bone (p<0.01) and calciﬁed
cartilage (p<0.02) was observed. Immunohistochemical staining
revealed lower MMP-13 and ADAMTS-5 levels (p<0.05) in car-
